Moxifloxacin (400 mg)

DRUG4 trials

Sponsors

Kythera Biopharmaceuticals, Shijiazhuang Yiling Pharmaceutical Co. Ltd, Alumis Inc, Nishtar Medical University

Conditions

AbscessAcute Myeloid Leukemia With FLT3/ITD MutationCellulitisCellulitis of FaceHealthyHealthy VolunteerMaxillofacial InfectionOdontogenic Infection

Phase 1

Evaluation of the Effect of ATX-101 on QT/QTc Intervals

CompletedNCT01706679

Kythera BiopharmaceuticalsHealthy

Start: 2012-10-31End: 2013-06-30Updated: 2013-11-14

A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants

RecruitingNCT07162116

Shijiazhuang Yiling Pharmaceutical Co. LtdAcute Myeloid Leukemia With FLT3/ITD Mutation

Start: 2025-07-06End: 2026-05-31Target: 45Updated: 2025-09-09

An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001

CompletedNCT07378579

Alumis IncHealthy Volunteer

Start: 2024-06-21End: 2024-08-31Updated: 2026-01-30

Unknown Phase

Moxifloxacin Versus Clindamycin in the Management of Odontogenic Maxillofacial Infectious Processes

Not yet recruitingNCT07810244

Nishtar Medical UniversityOdontogenic Infection, Maxillofacial Infection, Cellulitis +2

Start: 2026-10-01End: 2027-02-15Target: 60Updated: 2026-09-09